- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Palovarotene, Placebo
- Drug
- Lead sponsor
- Clementia Pharmaceuticals Inc.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- San Francisco, California • Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Not listed
- Lead sponsor
- Clementia Pharmaceuticals Inc.
- Industry
- Eligibility
- Up to 65 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 2
- States / cities
- San Francisco, California • Philadelphia, Pennsylvania
- Conditions
- Exostoses, Multiple Hereditary
- Interventions
- Palovarotene 2.5 mg, Palovarotene 5.0 mg, Placebo
- Drug · Other
- Lead sponsor
- Clementia Pharmaceuticals Inc.
- Industry
- Eligibility
- 2 Years to 14 Years
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Sacramento, California • San Francisco, California + 9 more
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Palovarotene dose level 1, Palovarotene dose level 2, Palovarotene dose level 3, Palovarotene dose level 4
- Drug
- Lead sponsor
- Clementia Pharmaceuticals Inc.
- Industry
- Eligibility
- 6 Years to 65 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 3
- States / cities
- San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Palovarotene
- Drug
- Lead sponsor
- Clementia Pharmaceuticals Inc.
- Industry
- Eligibility
- 6 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- San Francisco, California • Philadelphia, Pennsylvania
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Palovarotene
- Drug
- Lead sponsor
- Clementia Pharmaceuticals Inc.
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 4
- States / cities
- San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Palovarotene, midazolam
- Drug
- Lead sponsor
- Clementia Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- IPN60130, Placebo
- Drug
- Lead sponsor
- Clementia Pharmaceuticals Inc.
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 4
- States / cities
- San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania